Comparative Pharmacology
Head-to-head clinical analysis: ASMANEX HFA versus TRIAMCINOLONE ACETONIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASMANEX HFA versus TRIAMCINOLONE ACETONIDE.
ASMANEX HFA vs TRIAMCINOLONE ACETONIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mometasone furoate is a corticosteroid that exerts anti-inflammatory effects by inhibiting multiple inflammatory cell types and mediators, including eosinophils, mast cells, macrophages, and lymphocytes, and reducing the release of pro-inflammatory cytokines and chemokines.
Corticosteroid that binds to glucocorticoid receptors, leading to inhibition of phospholipase A2, decreased prostaglandin and leukotriene synthesis, and suppression of inflammatory cytokines.
2 inhalations (100 mcg each) twice daily orally, maximum 400 mcg/day.
Intramuscular: 40-80 mg every 4 weeks. Intra-articular: 5-40 mg depending on joint size. Topical: Apply thin film to affected area 2-4 times daily.
None Documented
None Documented
The terminal elimination half-life of mometasone furoate following inhalation is approximately 25 hours (range 15–40 hours), reflecting slow absorption from the lungs and prolonged systemic clearance.
Terminal elimination half-life approximately 2-5 hours; but suppression of adrenal function (HPA axis) can persist for 7-30 days depending on dose and duration.
Following oral inhalation, the absorbed fraction of mometasone furoate is extensively metabolized in the liver. Excretion is primarily via feces (approximately 74%) and urine (approximately 8%) as metabolites. Biliary excretion contributes to fecal elimination.
Renal (primarily as metabolites, <5% unchanged); biliary/fecal (minor).
Category C
Category D/X
Corticosteroid, Inhaled
Corticosteroid